A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
This study evaluated the efficacy and safety of the combination of peginterferon alfa-2a plus
ribavirin in treatment-naïve patients with HCV genotype 1b infection, compared with
peginterferon alfa-2a monotherapy.
Additionally, the study evaluated the efficacy and safety of the combination of peginterferon
alfa-2a plus ribavirin in patients with CHC who had failed to respond to previous
conventional-interferon based therapy.